Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2013 1
2014 1
2018 1
2020 1
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
First description of Nodding Syndrome in the Central African Republic.
Metanmo S, Boumédiène F, Preux PM, Colebunders R, Siewe Fodjo JN, de Smet E, Yangatimbi E, Winkler AS, Mbelesso P, Ajzenberg D. Metanmo S, et al. Among authors: de smet e. PLoS Negl Trop Dis. 2021 Jun 18;15(6):e0009430. doi: 10.1371/journal.pntd.0009430. eCollection 2021 Jun. PLoS Negl Trop Dis. 2021. PMID: 34143783 Free PMC article.
Surveillance for Onchocerciasis-Associated Epilepsy and OV16 IgG4 Testing of Children 6-10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening.
Dusabimana A, Siewe Fodjo JN, Ndahura MM, Mmbando BP, Jada SR, Boven A, De Smet E, Ukety T, Njamnshi AK, Laudisoit A, Abrams S, Colebunders R. Dusabimana A, et al. Among authors: de smet e. Pathogens. 2022 Feb 23;11(3):281. doi: 10.3390/pathogens11030281. Pathogens. 2022. PMID: 35335605 Free PMC article.
Correction: Dusabimana et al. Surveillance for Onchocerciasis-Associated Epilepsy and Ov16 IgG4 Testing of Children 6-10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening. Pathogens 2022, 11, 281.
Dusabimana A, Siewe Fodjo JN, Ndahura MM, Mmbando BP, Jada SR, Boven A, De Smet E, Ukety T, Njamnshi AK, Laudisoit A, Abrams S, Colebunders R. Dusabimana A, et al. Among authors: de smet e. Pathogens. 2022 Jun 30;11(7):746. doi: 10.3390/pathogens11070746. Pathogens. 2022. PMID: 35890065 Free PMC article.
Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.
van Pesch V, Bartholomé E, Bissay V, Bouquiaux O, Bureau M, Caekebeke J, Debruyne J, Declercq I, Decoo D, Denayer P, De Smet E, D'hooghe M, Dubois B, Dupuis M, Sankari SE, Geens K, Guillaume D, van Landegem W, Lysandropoulos A, de Noordhout AM, Medaer R, Melin A, Peeters K, Ba RP, Retif C, Seeldrayers P, Symons A, Urbain E, Vanderdonckt P, Van Ingelghem E, Vanopdenbosch L, Vanroose E, Van Wijmeersch B, Willekens B, Willems C, Sindic C. van Pesch V, et al. Among authors: de smet e. Acta Neurol Belg. 2014 Sep;114(3):167-78. doi: 10.1007/s13760-014-0308-9. Epub 2014 Jun 11. Acta Neurol Belg. 2014. PMID: 24915752
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators. Trojano M, et al. Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2. Mult Scler Relat Disord. 2018. PMID: 29860197 Free article.